Correction to: Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis

Carlos Escobar¹ · Vivencio Barrios² · Gregory Y. H. Lip³ · Alpesh N. Amin⁴ · Ariadna Auladell-Rispau⁵ · Marilina Santero⁵ · Josefina Salazar⁵ · Carolina Requeijo⁵

Published online: 14 February 2022
© Springer Nature Switzerland AG 2022

Correction to: Clinical Drug Investigation
<https://doi.org/10.1007/s40261-021-01091-w>

The original version of this article unfortunately contained a mistake. Page 950, Table 1: row 3 in column 7—GI bleeding, which previously read Y ↑ should read Limit ↑.

Corrected Table 1 is given in the following page.

The original article can be found online at <https://doi.org/10.1007/s40261-021-01091-w>.

✉ Carlos Escobar
escobar_cervantes_carlos@hotmail.com

¹ Servicio de Cardiología, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain

² Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain

³ University of Liverpool and Liverpool Heart and Chest, Liverpool, UK

⁴ Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA

⁵ Grup de Recerca d'Epidemiologia Clínica i Serveis Sanitaris, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain

Table 1 Effectiveness and safety summary of the results

		Primary outcomes				Secondary outcomes					
		Ischemic stroke	Ischemic stroke/SE	Major bleeding	Intracranial bleeding	Fatal bleeding	GI bleeding	Systemic embolism	Myocardial infarction	Pulmonary embolism	Mortality
	Efficacy	Efficacy	Efficacy	Safety	Safety	Safety	Safety	Efficacy	Efficacy	Efficacy	
Number of studies	17	8		20	16	5	23	2	16	1	17
Globally	N	Y ↓		Y ↓	Y ↓	Y ↓	Y ↑	Limit ↓	Limit ↓	N	Y ↓
150 mg	Y ↓	Limit ↓		Y ↓	Y ↓	N	Limit ↑	N	Limit ↓	N	Y ↓
110 mg	N	Y ↓		Y ↓	Y ↓	N	Limit ↑	Y ↓	N	NA	Limit ↓

GI gastrointestinal, *Limit* no difference but close to statistical significance, *N* no difference, *NA* not assessed, *SE* systemic embolism, *Y* statistically significant difference, ↓ risk reduction, ↑ increased risk